EMBO Molecular Medicine (Aug 2013)

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses

  • Diana J. Azzam,
  • Dekuang Zhao,
  • Jun Sun,
  • Andy J. Minn,
  • Prathibha Ranganathan,
  • Katherine Drews‐Elger,
  • Xiaoqing Han,
  • Manuel Picon‐Ruiz,
  • Candace A. Gilbert,
  • Seth A. Wander,
  • Anthony J. Capobianco,
  • Dorraya El‐Ashry,
  • Joyce M. Slingerland

DOI
https://doi.org/10.1002/emmm.201302558
Journal volume & issue
Vol. 5, no. 10
pp. 1502 – 1522

Abstract

Read online

Abstract Increasing evidence suggests that stem‐like cells mediate cancer therapy resistance and metastasis. Breast tumour‐initiating stem cells (T‐ISC) are known to be enriched in CD44+CD24neg/low cells. Here, we identify two T‐ISC subsets within this population in triple negative breast cancer (TNBC) lines and dissociated primary breast cancer cultures: CD44+CD24low+ subpopulation generates CD44+CD24neg progeny with reduced sphere formation and tumourigenicity. CD44+CD24low+ populations contain subsets of ALDH1+ and ESA+ cells, yield more frequent spheres and/or T‐ISC in limiting dilution assays, preferentially express metastatic gene signatures and show greater motility, invasion and, in the MDA‐MB‐231 model, metastatic potential. CD44+CD24low+ but not CD44+CD24neg express activated Notch1 intracellular domain (N1‐ICD) and Notch target genes. We show N1‐ICD transactivates SOX2 to increase sphere formation, ALDH1+ and CD44+CD24low+cells. Gamma secretase inhibitors (GSI) reduced sphere formation and xenograft growth from CD44+CD24low+ cells, but CD44+CD24neg were resistant. While GSI hold promise for targeting T‐ISC, stem cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T‐ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti‐cancer drug responsiveness.

Keywords